What was known before {#section11-2054358117734534}
=====================

Chronic kidney disease (CKD) is commonly associated with menstrual disorders, infertility, and premature menopause. Nephrologists are often considered as the primary care providers by their patients, but perceptions of nephrologists and renal allied health care providers on management of these issues are currently unknown.

What this adds {#section12-2054358117734534}
==============

While nephrologists and allied health care providers recognize the impact of CKD on sex hormone status in women, they reported not frequently discussing menstrual disorders, fertility, and menopause with their female patients with CKD, highlighting an important knowledge gap in nephrology.

Introduction {#section13-2054358117734534}
============

Chronic kidney disease (CKD) affects 8% to 16% of individuals globally.^[@bibr1-2054358117734534]^ In women with CKD, disruptions in gonadotropin-releasing hormone (GnRH) production result in an abnormal sex hormone profile, ultimately resulting in low levels of estradiol^[@bibr2-2054358117734534][@bibr3-2054358117734534]-[@bibr4-2054358117734534]^ and commonly leading to early menopause, menstrual disorders, and infertility in women with both dialysis and non-dialysis-dependent CKD.^[@bibr5-2054358117734534]^ Fertility rates among women of childbearing age with CKD are low,^[@bibr6-2054358117734534][@bibr7-2054358117734534][@bibr8-2054358117734534]-[@bibr9-2054358117734534]^ and complications to both mother and fetus are high when pregnancy occurs,^[@bibr9-2054358117734534],[@bibr10-2054358117734534]^ highlighting the importance of discussion of the potential risks of contraception^[@bibr11-2054358117734534][@bibr12-2054358117734534]-[@bibr13-2054358117734534]^ compared with the risks of pregnancy. The mean age at menopause is 4 years earlier in women with end-stage kidney disease (ESKD) compared with the general population.^[@bibr14-2054358117734534]^

International guidelines suggest that women with premature menopause in the general population use hormone therapy (HT) until the median age of natural menopause for symptom management,^[@bibr15-2054358117734534][@bibr16-2054358117734534][@bibr17-2054358117734534]-[@bibr18-2054358117734534]^ although this has never been addressed in guidelines relevant to the CKD population. Studies on the role of HT in the CKD population are limited.^[@bibr19-2054358117734534][@bibr20-2054358117734534][@bibr21-2054358117734534][@bibr22-2054358117734534][@bibr23-2054358117734534][@bibr24-2054358117734534]-[@bibr25-2054358117734534]^ Given the high prevalence of menstrual, pregnancy, and fertility disorders coupled with the early menopause observed in the CKD population, we sought to determine how health care providers in nephrology approach management of sex hormone status in women with CKD.

Methods {#section14-2054358117734534}
=======

Survey Development {#section15-2054358117734534}
------------------

A survey instrument ([Appendix 1](#app1-2054358117734534){ref-type="app"}) was developed with input from a group of 15 physicians (experts in the field of nephrology \[n = 13\], endocrinology \[n = 1\], and cardiology \[n = 1\]) and nephrology nurses (n = 3). Item generation was developed through a combination of literature review and consultation with experts in the field as outlined above. An assessment of the face validity, clarity, length, and completeness of the survey was performed through semistructured interviews (pre-testing) with nephrologists. The instrument was pilot tested on 6 nephrologists.

Survey Administration {#section16-2054358117734534}
---------------------

An e-mail cover letter explaining the purpose of the study and a link providing access to the secure, web-based survey were sent to 2441 members of the Canadian (n = 285) and Australia and New Zealand (n = 850) Nephrology Societies, the British Renal Society (n = 1306), and the Canadian Association of Nephrology Nurses and Technologists (n = 456) between February and November 2015. All physicians and allied health care providers (nurses and pharmacists) were recruited through memberships to these organizations. The study remained open 2 months after the initial e-mail contact. Reminder e-mails were sent up to 3 times, each at least 2 weeks apart. In addition, the survey was included in the monthly International Society of Nephrology (n = 9000) electronic newsletter for July and September 2015. The survey was disseminated in June 2015 and again in August 2015 via Twitter by the International Society of Nephrology.

Information was collected on demographics, type of nephrology practice, perceptions on discussion of fertility, menstrual cycle irregularities and menopause with patients, and opinions on use of postmenopausal HT in women with CKD. The responses for questions were assessed for frequency (never, rarely, sometimes, often, or always) or agreement (strongly disagree, disagree, neither agree nor disagree, agree, strongly agree, or I do not know). In addition, each question included an optional free form comment section. Clinical sensibility was assessed by reviewing the comments from the survey sent to the Canadian Society of Nephrology, and the survey was modified to include a question to further assess type of practice (adult, pediatric, or both) such that the survey link to the British Renal Society, Australian and New Zealand Society of Nephrology, the International Society of Nephrology, and the Canadian Association of Nephrology Nurses and Technologists included a question regarding pediatric versus adult nephrology practice.

Ethics approval for the study was obtained from the University of Calgary Conjoint Health Research Ethics Board. Participation in the study was voluntary, and informed consent was obtained electronically as part of the survey.

Data Analysis {#section17-2054358117734534}
-------------

The primary goal was to describe the perceptions of nephrologists and allied health care providers on the importance and frequency of discussing sex hormone status with their female patients with CKD, and their opinions on use of HT in women with CKD. We compared the responses from female and male nephrologists, as it has been reported that physicians use fewer resources to treat the genital-specific conditions of same-sex patients.^[@bibr26-2054358117734534]^ All data were used to conduct stratified statistical analyses using the Pearson chi-squared test. Further comparisons were made between transplant and nontransplant nephrologists, physicians, and allied health care workers and geographical location using ordinal logistic and logistic regressions. For the qualitative analysis, each free form response was analyzed collectively by 2 reviewers (S.R. and S.B.A.), comments were reduced to broader themes by inductively developing categories, and recurrent ideas were grouped into themes which were then reported. There was consensus between the 2 reviewers.

Results {#section18-2054358117734534}
=======

Demographics {#section19-2054358117734534}
------------

There were 296 respondents (158 nephrologists, 17 medical trainees in nephrology, 121 nephrology allied health care providers \[116 nurses and 5 pharmacists\]) to the survey. The average response rate was 21.2% (47%, 8.4%, 1.3%, and 28%, respectively, for the Canadian Society of Nephrology, British Renal Society, Australian and New Zealand Society of Nephrology, and Canadian Association of Nephrology Nurses and Technologists). In addition, 0.2% of the membership from the International Society of Nephrology responded to the survey, though the low response rate was expected due to the fact that the Canadian and Australia and New Zealand Societies of Nephrology also form part of the International Society of Nephrology.

[Table 1](#table1-2054358117734534){ref-type="table"} summarizes the demographic characteristics of the respondents. Sixty-eight percent of the nephrologists were between the ages of 30 and 50 years, and 38% of nephrologists were female. There was a broad range in terms of length of practice with the majority practicing nephrology in a clinical and academic setting. Twenty percent of the physicians were transplant nephrologists. Of the 55 nephrologists and trainees in nephrology respondents where this information was available, 4% of nephrologist respondents were primarily involved in pediatric practice.

###### 

Baseline Characteristics of All Respondents.

![](10.1177_2054358117734534-table1)

                                                                                        Nephrologist and medical trainees   Allied health care provider                                
  ------------------------------------------------------------------------- ----------- ----------------------------------- ----------------------------- ------ ----------- --------- ------
  Age, y                                                                                                                                                  .04                          .18
   \<30                                                                     5.74        4.63                                13.43                                1.85        7.69      
   30-40                                                                    25.34       34.33                               31.48                                14.81       15.38     
   41-50                                                                    34.12       35.82                               36.11                                28.7        53.85     
   51-60                                                                    30.07       10.45                               22.22                                50.93       23.08     
   61-70                                                                    3.38        5.97                                1.85                                 3.7         0         
   \>70                                                                     1.35        0                                   3.7                                  0           0         
  Years of practice                                                                                                                                       .528                         .01
   \<5                                                                      15.88       29.85                               19.44                                2.78        23.08     
   5-10                                                                     16.55       20.9                                23.15                                6.48        23.08     
   10-15                                                                    19.59       23.88                               24.07                                12.96       15.38     
   15-20                                                                    11.15       11.94                               10.19                                12.04       7.69      
   20-25                                                                    10.47       4.48                                8.33                                 16.67       7.69      
   \> 25                                                                    26.35       8.96                                14.81                                49.07       23.08     
  Type of practice^[a](#table-fn1-2054358117734534){ref-type="table-fn"}^                                                                                                              
   Clinical                                                                 65.54       61.19                               63.89                                72.22       46.15     
   Academic                                                                 61.73       50.75                               68.52                                9.26        23.08     
   Community                                                                12.84       11.94                               12.96                                13          15.38     
   Research                                                                 19.93       32.84                               20.37                                12.03       15.38     
   Education                                                                27.36       31.34                               22.22                                30.56       23.08     
   Administrative                                                           11.49       14.93                               12.04                                8.33        15.38     
  Transplant                                                                                                                                              .351                         .2
   Yes                                                                      11.82       16.42                               22.22                                1.85        7.69      
   No                                                                       88.18       83.58                               77.78                                98.15       92.31     
  Patient population                                                        (n = 168)   (n = 26)                            (n = 31)                      .086   (n = 103)   (n = 8)   .351
   Adult                                                                    93.45       92.31                               90.32                                95.15       87.5      
   Pediatric                                                                2.38        0                                   9.68                                 1.94        0         
   Both                                                                     4.17        7.69                                0                                    2.91        12.5      

Categories not mutually exclusive.

Forty-six percent of the allied health care providers (nurses and pharmacists) were between the ages of 30 and 50 years and 89% of them were female. Fifty-six percent of the allied health care respondents reported being in nephrology practice for greater than 25 years. None of the allied health care respondents worked primarily with a transplant population, and 2% reported being primarily involved in pediatric practice.

Impact of Kidney Disease on Sex Hormones and Discussion of Symptoms {#section20-2054358117734534}
-------------------------------------------------------------------

The perceptions of nephrologists on sex hormone status and kidney function are summarized in [Figures 1](#fig1-2054358117734534){ref-type="fig"} to [4](#fig4-2054358117734534){ref-type="fig"}. Ninety-five percent of the respondents strongly agreed or agreed that kidney function has an important effect on sex hormone status, but only a third of respondents reported often or always discussing fertility and even fewer (15%) reported always or often discussing menstrual irregularities with their female patients of childbearing age. Although there were no statistically significant differences between female and male nephrologists in how often they reported discussing fertility (*P* = .06), female nephrologists reported more frequently discussing menstrual irregularities with their patients (*P* = .02) ([Figure 1](#fig1-2054358117734534){ref-type="fig"}). Transplant nephrologists were more likely to report discussing fertility with their female patients (53% transplant vs 30% nontransplant nephrologist, *P* = .03). There were no differences based on geographical location of the respondents. As only 4% of the nephrologists reported having a mainly pediatric practice, we were unable to analyze the difference between adult and pediatric nephrologists.

![Nephrologists' impressions of sex hormone status in chronic kidney disease.](10.1177_2054358117734534-fig1){#fig1-2054358117734534}

![Nephrologists' impressions of patient discussion of sex hormone status in chronic kidney disease.](10.1177_2054358117734534-fig2){#fig2-2054358117734534}

![Nephrologists' impressions of hormone therapy in CKD.\
*Note.* CKD = chronic kidney disease; HRT = hormone replacement therapy.](10.1177_2054358117734534-fig3){#fig3-2054358117734534}

![Nephrologist impression on factors to consider for hormone therapy in CKD.\
*Note.* CKD = chronic kidney disease; HRT = hormone replacement theory.](10.1177_2054358117734534-fig4){#fig4-2054358117734534}

Thirteen percent of respondents provided optional comments. The main themes that emerged from qualitative analyses were that discussions regarding fertility were focused on either contraception counseling in the setting of use of teratogenic drugs or pre--kidney transplant, or when prescribing drugs associated with the potential to cause ovarian failure. In addition, some physicians outlined that discussion of fertility with their patients was not warranted because the female patients in their practice were mainly older women.

Forty-eight percent of the nephrologists believed their female patients of childbearing age wished to discuss fertility and 15% to discuss menstrual status and menopause. Female nephrologists stated that their female patients brought up issues about fertility with them more frequently than did male nephrologists (*P* = .03); however, this gender difference was not observed for patients discussing menstrual status or menopause (*P* = .14; [Figure 2](#fig2-2054358117734534){ref-type="fig"}). Female patients were reported to bring up issues about fertility more often by transplant than nontransplant nephrologists (67% transplant vs 45% nontransplant nephrologist, *P* = .01). Despite respondents reporting that patients wished to discuss concerns associated with fertility and menstrual irregularities, only 35% of the respondents asked patients to address these concerns with their family physician or another physician (endocrinologist or gynecologist). This was not different between female and male nephrologists (*P* = .53).

Among allied health care providers, 87% agreed or strongly agreed that kidney function has an important impact on sex hormone status; however, very few reported always or often discussing fertility (7.5%) or menstrual irregularities (9%) with their female patients. This was significantly different from that reported by physicians (fertility: *P* \< .001; menstrual irregularities: *P* = .04). Twenty-seven percent of allied health care providers agreed or strongly agreed that their female patients of childbearing age wished to discuss fertility often and 30% wished to discuss menstrual abnormalities or menopause. Allied health care providers were less likely to report that their female patients wished to discuss fertility (*P* \< .001) but more likely to report that female patients wished to discuss menstrual irregularities (*P* = .003) compared with physicians.

Postmenopausal HT {#section21-2054358117734534}
-----------------

Forty-three percent of the physicians reported an uncertainty for the role for postmenopausal HT in women with CKD; 17% agreed or strongly agreed that there is a role for HT in women with CKD. When asked whether the benefits of HT outweigh the risks in patients with CKD, 46% of the physicians reported they did not know ([Figure 3](#fig3-2054358117734534){ref-type="fig"}). Furthermore, 47% and 45% reported they did not know whether HT should be considered in perimenopausal and postmenopausal women with CKD, respectively.

Fifty-three percent of the respondents agreed or strongly agreed that the formulation of HT and whether it is used in conjunction with progesterone are important in women with a uterus, and 35% reported they did not know. Similarly, 37% agreed or strongly agreed that the route of HT administration is important, and 37% reported they did not know. Thirty-four percent of the physicians agreed or strongly agreed that the stage of CKD should be considered for HT use while 39% reported they did not know. When asked at what stage of CKD the benefits of HT outweigh the risks, 75% reported they did not know ([Figure 4](#fig4-2054358117734534){ref-type="fig"}).

Among allied health care professionals, 57% reported they did not know whether there is a role for HT in women with CKD and 58% reported they did not know whether the formulation of HT should be taken into consideration for women with CKD. Forty-one percent reported they did not know whether the route of administration is important to take into consideration for women with CKD.

When asked about HT prescription practice prior to the publication of the Women's Health Initiative (WHI) trials in 2002,^[@bibr27-2054358117734534]^ 47% of the physicians reported they were not in nephrology practice prior to 2002, 5.8% reported they often prescribed HT, and 37% reported they did not prescribe HT. In contrast, 83% stated they did not prescribe HT after the WHI trials were published. Among the 5% of physicians who provided written comments on HT prescription practice, some suggested that they were likely to recommend HT for symptom relief in their female patients with CKD ([Appendix 2](#app2-2054358117734534){ref-type="app"}). Thematic analysis of the comments from the survey is presented in [Appendix 2](#app2-2054358117734534){ref-type="app"}.

Discussion {#section22-2054358117734534}
==========

This cross-sectional survey examined the views of nephrologists and allied health care professionals on the impact of kidney disease on sex hormone status. We found that while nephrologists and allied health care professionals recognize the important effects of kidney disease on sex hormone status in women with CKD, reported discussion of the sequelae of low estradiol levels such as infertility, menstrual disorders, or premature menopause with their patients was limited. In addition, there was a high level of uncertainty in the nephrology community regarding the role of HT.

There was significant variability in the responses stratified by gender, transplant and nontransplant nephrologists, and physicians and allied health care providers. Female nephrologists were more likely to report discussing menstrual irregularities with their patients, and transplant nephrologists reported discussing fertility more often than nontransplant nephrologists. Physicians were more likely to report discussing fertility and menstrual irregularities with their female patients than allied health care providers. In addition, while only 35% of clinicians asked patients to address concerns associated with fertility and menstrual irregularities with their family doctor or refer them to another physician, this could be because few reported often discussing issues regarding fertility and menstrual irregularities with their patients.

Despite awareness that kidney disease--mediated abnormalities in sex hormone levels are common, nephrologists and allied health care workers reported uncertainties regarding the role for HT in the CKD population. The results of this study suggest that while the nephrology community is aware of the impact of CKD on sex hormone status with patients, incorporation of this knowledge into clinical practice is more limited.

In women with CKD, disruptions in GnRH production result in an abnormal sex hormone profile leading to low levels of estradiol, though the pathophysiology remains unclear.^[@bibr2-2054358117734534][@bibr3-2054358117734534]-[@bibr4-2054358117734534],[@bibr28-2054358117734534],[@bibr29-2054358117734534]^ Low levels of estradiol result in symptoms such as decrease in fertility and sexual desire, menstrual abnormalities, hot flashes, sleep disturbances, and mood changes which are associated with a decrease in quality of life, at least in women without CKD.^[@bibr30-2054358117734534][@bibr31-2054358117734534]-[@bibr32-2054358117734534]^ Fertility rates among women of childbearing age with CKD are low^[@bibr6-2054358117734534][@bibr7-2054358117734534]-[@bibr8-2054358117734534]^; however, complications to both mother and fetus are high when pregnancy occurs.^[@bibr10-2054358117734534]^ A study of 100 women with CKD reported that 88% had menstrual problems or were menopausal, with 20% of menopausal women being \<40 years of age.^[@bibr5-2054358117734534]^ A previous cross-sectional study examining gynecological issues in 76 women on dialysis showed that 59% of women reported irregular menses.^[@bibr33-2054358117734534]^ In addition, a meta-analysis of women with CKD found that the prevalence of sexual dysfunction as defined by decreased sexual desire ranged from 30% to 80%.^[@bibr34-2054358117734534]^ This suggests that women with CKD have a significant burden of signs and symptoms associated with low estradiol levels.

There may be several reasons why nephrologists reported not often discussing fertility, menstrual irregularities, and menopause with their female patients. First, they may feel this falls outside their domain of expertise or the primary purpose of their clinical encounter with the patient. Second, it has been shown that in patients with chronic conditions with multiple comorbidities, disease states not prominently related to the primary condition are often not addressed.^[@bibr35-2054358117734534]^ Given the disease burden of the average CKD patient, there may be inadequate time to address issues related to sex hormone status.^[@bibr36-2054358117734534],[@bibr37-2054358117734534]^ Third, as suggested by Cochrane and Regan,^[@bibr5-2054358117734534]^ although nephrologists are often considered the primary care provider by their patients,^[@bibr38-2054358117734534]^ women with CKD may not raise gynecological issues for discussion with their nephrologists as these concerns may appear less important in comparison with other kidney-related health issues. Transplant nephrologists reported discussing fertility with their female patients of childbearing age more often than nontransplant nephrologists. This could be due to the younger age of patients receiving transplant^[@bibr39-2054358117734534]^ and the recommendation to avoid pregnancy within the first 1 to 2 years of transplant, coupled with the necessary prescription of potentially teratogenic medications in this setting.

Women with kidney disease experience cessation of menses significantly earlier than do the general population, and while there are no CKD-specific recommendations, international guidelines suggest that women with premature menopause initiate HT until the natural age of menopause.^[@bibr15-2054358117734534][@bibr16-2054358117734534][@bibr17-2054358117734534]-[@bibr18-2054358117734534]^ Our survey highlights that nephrologists and other allied health care providers are not confident discussing or prescribing HT in women with CKD. The knowledge gap on this issue likely reflects the paucity of literature on HT in this population; few studies have examined the role of HT specifically in women with kidney disease.^[@bibr19-2054358117734534][@bibr20-2054358117734534][@bibr21-2054358117734534][@bibr22-2054358117734534][@bibr23-2054358117734534][@bibr24-2054358117734534]-[@bibr25-2054358117734534]^ It is possible that discussion of clinical sequelae of low estrogen levels is limited due to lack of evidence for a viable treatment option in this population. Further clinical trials are required to determine the effectiveness and safety of postmenopausal HT in women with CKD.

When and how to incorporate discussion regarding contraception, fertility, and menopause with the female CKD patient is beyond the scope of this study. However, raising these issues common to all women as part of the initial consult would ensure that patients and their health care providers recognize that kidney disease has an important impact on sexual, hormonal, and gynecologic aspects to their care.

Limitations {#section23-2054358117734534}
-----------

The limitations of our survey include the self-reported nature of the data, as well as the possibility of differences in practice between respondents and nonrespondents. The generalizability of our study may be limited. First, the physician sample self-identified as mainly nephrologists in academic practice and was derived through membership to nephrology societies of high-income countries, which may not accurately capture global practice. Second, the survey response rate was low; however, our average response rate of 21% is comparable with the typical 20% response rate to online surveys of clinicians.^[@bibr40-2054358117734534],[@bibr41-2054358117734534]^ Third, the majority of respondents were from the Canadian societies, and thus, the results of the survey primarily reflect perceptions from a Canadian perspective. Our sample may be enriched for female nephrologists, because 38% of the nephrologist respondents were women, as compared with a recent estimate of the proportion of female nephrologists (34%).^[@bibr42-2054358117734534]^ This was a preliminary survey designed to determine the initial impressions of nephrologists on the impact of sex hormones on CKD; as such, questions exploring reasons for the lack of discussion on CKD and sex hormones in a clinical setting were not explored. Further studies are required to better understand the conclusions of this study. This study is also limited by the lack of objective definitions of options like often and rarely; however, to avoid floor and ceiling effects of this Likert scale, we included several options in the Likert scale and an open-ended comment section. Nephrology practices commonly include elderly populations, and it is possible that increased patient age may play a role in the reported lack of discussion of sex hormone status and its sequelae; however, the survey questions were specific to age-appropriate patient populations. Lastly, studies have suggested that social desirability bias results in the tendency of survey respondents to answer questions in a manner that will be viewed favorably by others^[@bibr43-2054358117734534]^; thus, actual discussion rates of issues related to sex hormone status in women with CKD may be lower. However, a recent meta-analysis has suggested that computer-based survey may limit social desirability bias,^[@bibr44-2054358117734534]^ though this has been disputed.^[@bibr43-2054358117734534]^

Conclusion {#section24-2054358117734534}
==========

In an international survey of nephrologists and renal allied health care providers, we found that while physicians and allied health care providers were aware of the impact of CKD on sex hormone levels, discussion and management of menstrual irregularities, fertility, and menopausal status were reported to be relatively infrequent. There was a high level of uncertainty among nephrologists with regard to the role of HT in women with CKD. In identifying this important knowledge and practice gap, we have highlighted the need for further study of this common clinical issue in women with CKD and the need for education for clinicians and allied health care providers on advising women with CKD on infertility and menopause.
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Sex Hormones in Chronic Kidney Disease {#section25-2054358117734534}
======================================

**I understand the above stated purpose of this survey and consent to the use of my responses for the purpose of academic research:**

1.   ○ Yes

2.   ○ No

**Demographic Information**

1.  **1. Age**

2.   ○ 30-40 Years

3.   ○ 41-50 Years

4.   ○ 51-60 Years

5.   ○ 61-70 Years

6.   ○ \>70 Years

7.  **2. Sex**

8.   ○ Male

9.   ○ Female

10. **3. Years of Practice**

11.  ○ 5-10 Years

12.  ○ 10-15 Years

13.  ○ 15-20 Years

14.  ○ 20-25 Years

15.  ○ 25 Years

16. **4. How are you involved in nephrology practice?**

17.  ○ Nephrologist

18.  ○ Medical trainee in nephrology

19.  ○ Nurse practitioner

20.  ○ Nurse

21.  ○ Other (please specify) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

22. 5\. Type of Practice (check all that apply)

23.  ⧠ Academic

24.  ⧠ Community

25.  ⧠ Clinical

26.  ⧠ Education

27.  ⧠ Administrative

28.  ⧠ Research

29.  ⧠ Other (Please Specify) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

30. 6\. Are you a transplant nephrologist?

31.  ○ Yes

32.  ○ No

33. **7. What type of patients are in your practice?**

34.  ○ Pediatric

35.  ○ Adult

36.  ○ Both

**Please answer the following based on your personal clinical practice**

1.  **1. How often do you discuss fertility with your female patients of childbearing age? (Number of comments: 31)**

2.   ○ Never

3.   ○ Rarely

4.   ○ Sometimes

5.   ○ Often

6.   ○ Always

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img1-2054358117734534}

1.  **2. How often do you discuss menstrual irregularities with your female patients of childbearing age? (Number of comments: 17)**

2.   ○ Never

3.   ○ Rarely

4.   ○ Sometimes

5.   ○ Often

6.   ○ Always

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img2-2054358117734534}

1.  **3. How often do you ask patients to address concerns associated with fertility and menstrual irregularities with their family doctor or refer them to another physician (endocrinologists or gynecologists)? (Number of comments: 13)**

2.   ○ Never

3.   ○ Rarely

4.   ○ Sometimes

5.   ○ Often

6.   ○ Always

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img3-2054358117734534}

To what extent do you agree or disagree with the following statements:

1.  **4. Kidney function has an important impact on sex hormone levels, menstrual status, and fertility. (Number of comments: 3)**

2.   ○ Strongly Agree

3.   ○ Agree

4.   ○ Neutral

5.   ○ Disagree

6.   ○ Strongly Disagree

7.   ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img4-2054358117734534}

1.  **5. My female patients of childbearing age often wish to discuss fertility. (Number of comments: 15)**

2.   ○ Strongly Agree

3.   ○ Agree

4.   ○ Neutral

5.   ○ Disagree

6.   ○ Strongly Disagree

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img5-2054358117734534}

1.  **6. My female patients under the age of 55 often wish to discuss menstrual status and symptoms or treatment of menopause. (Number of comments: 13)**

2.   ○ Strongly Agree

3.   ○ Agree

4.   ○ Neutral

5.   ○ Disagree

6.   ○ Strongly Disagree

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img6-2054358117734534}

1.  **7. There is a role for postmenopausal hormone replacement therapy (HRT) in patients with CKD. (Number of comments: 15)**

2.   ○ Strongly Agree

3.   ○ Agree

4.   ○ Neutral

5.   ○ Disagree

6.   ○ Strongly Disagree

7.   ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img7-2054358117734534}

1.  **8. The benefits of HRT far outweigh the risks in patients with CKD. (Number of comments: 12)**

2.   ○ Strongly Agree

3.   ○ Agree

4.   ○ Neutral

5.   ○ Disagree

6.   ○ Strongly Disagree

7.   ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img8-2054358117734534}

1.  **9. In women with a uterus, the formulation of the hormone therapy and whether it used in conjunction with progesterone is important. (Number of comments: 6)**

2.   ○ Strongly Agree

3.   ○ Agree

4.   ○ Neutral

5.   ○ Disagree

6.   ○ Strongly Disagree

7.   ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img9-2054358117734534}

1.  **10. The route of administration of HRT (oral, transdermal, transvaginal) is important. (Number of comments: 2)**

2.    ○ Strongly Agree

3.   ○ Agree

4.    ○ Neutral

5.    ○ Disagree

6.    ○ Strongly Disagree

7.    ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img10-2054358117734534}

1.  **11. I often prescribed HRT PRIOR to the Women's Health Initiative (WHI) trials (JAMA 2002). (Number of comments: 18)**

2.    ○ Strongly Agree

3.   ○ Agree

4.    ○ Neutral

5.    ○ Disagree

6.    ○ Strongly Disagree

7.    ○ I Do Not Know

8.    ○ I was not in nephrology practice prior to 2002

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img11-2054358117734534}

1.  **12. I often prescribe HRT AFTER the Women's Health Initiative (WHI) trials (JAMA 2002). (Number of comments: 28)**

2.    ○ Strongly Agree

3.    ○ Agree

4.    ○ Neutral

5.    ○ Disagree

6.    ○ Strongly Disagree

7.    ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img12-2054358117734534}

1.  **13. Stage of CKD is important when considering HRT use. (Number of comments: 6)**

2.    ○ Strongly Agree

3.    ○ Agree

4.    ○ Neutral

5.    ○ Disagree

6.    ○ Strongly Disagree

7.    ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img13-2054358117734534}

1.  **14. The benefits of HRT outweigh the risks in the following stages of CKD (check all that apply). (Number of comments: 9)**

2.    ⧠ Stage 1 CKD

3.    ⧠ Stage 2 CKD

4.    ⧠ Stage 3a CKD

5.    ⧠ Stage 3b CKD

6.    ⧠ Stage 4 CKD

7.    ⧠ Stage 5 CKD

8.    ⧠ Stage 5 D CKD

9.    ⧠ I do not know

10.   ⧠ HRT should never be prescribed to CKD patients

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img14-2054358117734534}

1.  **15. HRT use should be considered in perimenopausal women with CKD. (Number of comments: 12)**

2.    ○ Strongly Agree

3.    ○ Agree

4.    ○ Neutral

5.    ○ Disagree

6.    ○ Strongly Disagree

7.    ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img15-2054358117734534}

1.  **16. HRT use should be considered in postmenopausal women with CKD. (Number of comments: 17)**

2.    ○ Strongly Agree

3.    ○ Agree

4.    ○ Neutral

5.    ○ Disagree

6.    ○ Strongly Disagree

7.    ○ I Do Not Know

**Comments (optional)**

![](10.1177_2054358117734534-img1.jpg){#img16-2054358117734534}

1.  1. How often do you discuss fertility with your female patients of childbearing age? (n = 31)

![](10.1177_2054358117734534-table2)

  -------------------------------------------------------------------------------------------------------------
  Fertility discussed if prescribing angiotensin converting enzyme inhibitor or angiotension receptor blocker
  Fertility discussed if patient was undergoing a transplant or post transplant
  Fertility discussed if patient was having immunosuppression
  -------------------------------------------------------------------------------------------------------------

1.  2.How often do you discuss menstrual irregularities with your female patients of childbearing age? (n = 17)

![](10.1177_2054358117734534-table3)

  ---------------------------------------------------------
  Patient asked to discuss this with general practitioner
  If patient has dysmenorrhea
  ---------------------------------------------------------

1.  3. How often do you ask patients to address concerns associated with fertility and menstrual irregularities with their family doctor or refer them to another physician (endocrinologists or gynecologists)? (n = 13)

![](10.1177_2054358117734534-table4)

  ---------------------------------------
  Referred for discussing birth control
  Referred based on patient concerns
  ---------------------------------------

1.  4. Kidney function has an important impact on sex hormone levels, menstrual status, and fertility. (n = 3)

![](10.1177_2054358117734534-table5)

  -------------------------------
  Not aware of any associations
  -------------------------------

1.  5. My female patients of childbearing age often wish to discuss fertility. (n = 15)

![](10.1177_2054358117734534-table6)

  ---------------------------------------
  Patient dependent
  Patients want to talk post-transplant
  Depends on stage of CKD
  ---------------------------------------

1.  6. My female patients under the age of 55 often wish to discuss menstrual status and symptoms or treatment of menopause. (n = 13)

![](10.1177_2054358117734534-table7)

  ---------------------------------------------------------
  Patients only bring it up if significant symptoms occur
  Patients bring it up in pre-dialysis clinic
  ---------------------------------------------------------

1.  7. There is a role for postmenopausal hormone replacement therapy (HRT) in patients with CKD. (n = 16)

![](10.1177_2054358117734534-table8)

  -----------------------------------------------------
  Only in symptomatic women
  Lack of strong evidence supporting HRT
  Have to take cardiovascular risk into consideration
  -----------------------------------------------------

1.  8. The benefits of HRT far outweigh the risks in patients with CKD. (n = 12)

![](10.1177_2054358117734534-table9)

  -------------------------------------------------------------
  Not according to recommendations or evidence
  CKD patients have a higher risk than the general population
  Dependent on quality of life versus heart disease
  -------------------------------------------------------------

1.  9. In women with a uterus, the formulation of the hormone therapy and whether it used in conjunction with progesterone is important. (n = 10)

![](10.1177_2054358117734534-table10)

  -----------------------------------------------
  Similar to the general population
  Have to consider long term risk of malignancy
  Not aware for CKD population
  -----------------------------------------------

1.  10. The route of administration of HRT (oral, transdermal, transvaginal) is important. (n = 2)

![](10.1177_2054358117734534-table11)

  -------------------
  Patient dependent
  -------------------

1.  11. I often prescribed HRT PRIOR to the Women's Health Initiative (WHI) trials (JAMA 2002). (n = 18)

All comments regarding not being licensed to prescribe

1.  12. I often prescribe HRT AFTER the Women's Health Initiative (WHI) trials (JAMA 2002). (n = 28)

All comments regarding not being licensed to prescribe

1.  13. Stage of CKD is important when considering HRT use. (n = 6)

![](10.1177_2054358117734534-table12)

  -----------------------------
  There is a lack of evidence
  -----------------------------

1.  14. The benefits of HRT outweigh the risks in the following stages of CKD (check all that apply). (n = 9)

![](10.1177_2054358117734534-table13)

  --------------------------------------------------------------------
  They may for the short term
  If patients are symptomatic
  Dependent on outcome -- quality of life versus cardiovascular risk
  --------------------------------------------------------------------

1.  15. HRT use should be considered in perimenopausal women with CKD. (n = 12)

![](10.1177_2054358117734534-table14)

  --------------------------------------------------------------
  If the patient is symptomatic
  Dependent on patient preference
  Dependent on risk of cardiovascular disease and osteoporosis
  --------------------------------------------------------------

1.  16. HRT use should be considered in postmenopausal women with CKD. (n = 17)

![](10.1177_2054358117734534-table15)

  -----------------------
  Dependent on symptoms
  Insufficient evidence
  -----------------------
